Screening Libraries

Product Data Sheet

MAC-545496

Cat. No.: HY-130613 CAS No.: 838810-96-1 Molecular Formula: $C_{18}H_{18}CIN_{5}O_{3}S$

Molecular Weight: 419.89 Target: Bacterial Pathway: Anti-infection

Storage: Powder -20°C 3 years

2 years In solvent -80°C 6 months

> -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 250 mg/mL (595.39 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3816 mL	11.9079 mL	23.8158 mL
	5 mM	0.4763 mL	2.3816 mL	4.7632 mL
	10 mM	0.2382 mL	1.1908 mL	2.3816 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

MAC-545496 is a nanomolar inhibitor of glycopeptide-resistance-associated protein R (GraR). MAC-545496 displays strong binding affinity to the full-length GraR protein ($K_d \le 0.1 \text{ nM}$). MAC-545496 is an antivirulence agent that reverses β -lactam resistance in Methicillin-resistant strains (MRSA)^[1].

IC₅₀ & Target

Glycopeptide-resistance-associated protein R (GraR)^[1]

In Vitro

MAC-545496 potently synergizes with Cefuroxime; concentrations as low as 0.03 μ g/mL (~75 nM) lowers the β -lactam MIC from 512 to 8 µg/mL against S. aureus USA300. MAC545496 also synergizes with Cefuroxime and Oxacillin against a collection of ten S. aureus clinical isolates. In addition, MAC-545496 potentiates the effect of Cefuroxime against representatives of other circulating MRSA strains such as USA100, USA400 and USA500 to different extents, with the exception of CMRSA4, a USA200/EMRSA16 isolate. MAC-545496 also synergizes with the antimicrobial peptides colistin and polymyxin $B^{[1]}$.

MAC-545496 shows inhibition of mprF expression in a concentration-dependent manner; the IC₅₀ value is 0.0376 μg/mL^[1]. MAC-545496 also inhibits the citrateinduced biofilm formation in the wild type in a concentration dependent manner^[1]. $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$

In Vivo

In vivo, MAC-545496 is effective as a monotherapy for MRSA infected Galleria mellonella larvae. MAC-545496 activity is evidenced by increased survival of the drug-treated larvae as compared to infected untreated ones. This corresponded to concentration-dependent killing of S. aureus in the hemolymph of the larvae observed from the CFUs recovered from the hemolymph 200 min after infection. Treatment of S. aureus-infected larvae with MAC-545496 occurred 30min after infection that mimics acquiring bacterial infection before initiating antimicrobial therapy [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. El-Halfawy OM, et al. Discovery of an antivirulence compound that reverses β-lactam resistance in MRSA. Nat Chem Biol. 2019 Nov 25.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA